S.Biomedics Co. Ltd.
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson's disease; FECS-Ad, which is 1/2a for the treatment of criti… Read more
S.Biomedics Co. Ltd. (304360) - Total Liabilities
Latest total liabilities as of March 2025: ₩33.89 Billion KRW
Based on the latest financial reports, S.Biomedics Co. Ltd. (304360) has total liabilities worth ₩33.89 Billion KRW as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
S.Biomedics Co. Ltd. - Total Liabilities Trend (2022–2024)
This chart illustrates how S.Biomedics Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
S.Biomedics Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of S.Biomedics Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Road Environment Technology Co. Ltd. A
SHG:688156
|
China | CN¥811.10 Million |
|
Yibin Paper Industry Co Ltd
SHG:600793
|
China | CN¥2.93 Billion |
|
Shanghai W Ibeda High Tech Group Co Ltd
SHG:688071
|
China | CN¥1.23 Billion |
|
Jiangsu Canopus Wisdom Medical Technology Co. Ltd. A
SHE:301290
|
China | CN¥238.50 Million |
|
Sansec Technology Co. Ltd. A
SHG:688489
|
China | CN¥178.89 Million |
|
Ganzhou Yihao New Materials Co. Ltd. A
SHE:301176
|
China | CN¥1.36 Billion |
|
Beijing Bashi Media Co Ltd
SHG:600386
|
China | CN¥2.50 Billion |
|
InBody Co.Ltd
KQ:041830
|
Korea | ₩36.31 Billion |
Liability Composition Analysis (2022–2024)
This chart breaks down S.Biomedics Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.54 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how S.Biomedics Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for S.Biomedics Co. Ltd. (2022–2024)
The table below shows the annual total liabilities of S.Biomedics Co. Ltd. from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩32.74 Billion | +30.86% |
| 2023-12-31 | ₩25.02 Billion | -11.09% |
| 2022-12-31 | ₩28.14 Billion | -- |